Vivek Subbiah, Chief of Early-Phase Drug Development at Sarah Cannon Research Institute (SCRI), shared a post on X:
“Hot off the press! Thrilled to share our latest paper in npj Precision Oncology “A unified framework for pre-screening and screening tools in oncology clinical trials”
Clinical trial enrollment faces mounting challenges-complex eligibility criteria, biomarker stratification, fragmented data.
We review the landscape from manual workflows to AI-enabled approaches, examining how LLMs and hybrid frameworks can improve matching efficiency, equity, & access to investigational therapies ”
Other OncoDaily articles featuring Vivek Subbiah.